141 related articles for article (PubMed ID: 33135164)
1. Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma.
Sun C; Liu M; Zhang W; Wang S; Qian G; Wang M; Zhang G
J Cell Physiol; 2021 May; 236(5):3821-3831. PubMed ID: 33135164
[TBL] [Abstract][Full Text] [Related]
2. ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment.
Chen WJ; Yang W; Gong M; He Y; Xu D; Chen JX; Chen WJ; Li WY; Wang YQ; Dong KQ; Song X; Pan XW; Cui XG
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562383
[TBL] [Abstract][Full Text] [Related]
3. ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia.
Liu CC; Wang H; Wang WD; Wang L; Liu WJ; Wang JH; Geng QR; Lu Y
Cell Physiol Biochem; 2018; 46(4):1525-1535. PubMed ID: 29689546
[TBL] [Abstract][Full Text] [Related]
4. Integrated Analysis of the Role of Enolase 2 in Clear Cell Renal Cell Carcinoma.
Pan J; Jin Y; Xu X; Wei W; Pan H
Dis Markers; 2022; 2022():6539203. PubMed ID: 36419844
[TBL] [Abstract][Full Text] [Related]
5. hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.
Dong X; Kong C; Zhang Z; Liu X; Zhan B; Chen Z; Shi D
Urol Oncol; 2014 Aug; 32(6):885-92. PubMed ID: 24878177
[TBL] [Abstract][Full Text] [Related]
6. Correlating Transcriptional Networks to Papillary Renal Cell Carcinoma Survival: A Large-Scale Coexpression Analysis and Clinical Validation.
Feng X; Zhang M; Meng J; Wang Y; Liu Y; Liang C; Fan S
Oncol Res; 2020 May; 28(3):285-297. PubMed ID: 31948514
[TBL] [Abstract][Full Text] [Related]
7. Glycolysis-Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma.
Zhang Y; Chen M; Liu M; Xu Y; Wu G
Oxid Med Cell Longev; 2021; 2021():6699808. PubMed ID: 33564363
[TBL] [Abstract][Full Text] [Related]
8. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
[TBL] [Abstract][Full Text] [Related]
9. Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development.
Gao L; Yang F; Tang D; Xu Z; Tang Y; Yang D; Sun D; Chen Z; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):1. PubMed ID: 36588153
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
[TBL] [Abstract][Full Text] [Related]
13. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
[TBL] [Abstract][Full Text] [Related]
14. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
15. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
[TBL] [Abstract][Full Text] [Related]
16. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
17. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
[TBL] [Abstract][Full Text] [Related]
18. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
19. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
[TBL] [Abstract][Full Text] [Related]
20. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
Ma X; Fan Y; Gao Y; Zhang Y; Huang Q; Ai Q; Ni D; Chen W; Zhang P; Song E; Wang B; Shi T; Zheng T; Zhang X
Urol Oncol; 2014 Jan; 32(1):46.e9-17. PubMed ID: 24094887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
